5847 |
Safety and Efficacy of TAVR for Pure AR in Native Valves: Results from a Multi-Center Registry |
Junjie Zhang |
Aug. 04. 23 |
5846 |
TEER for Functional MR: When and How? |
Shih-Hsien Sung |
Aug. 04. 23 |
5845 |
Current Status of TEER in Korea : AMC Experience |
Do-Yoon Kang |
Aug. 04. 23 |
5844 |
CEP in TAVR - From Rationale, Practical Viewpoint and Data Updates |
Cheung Chi Simon Lam |
Aug. 04. 23 |
5843 |
TAVR for Bicuspid AV: What¡¯s Different? |
Jung-Min Ahn |
Aug. 04. 23 |
5842 |
New Device Platform to Prevent Structural Heart Intervention Complications |
Alan C. Yeung |
Aug. 04. 23 |
5841 |
10 Year's Journey of AMC TAVR |
Seung-Jung Park |
Aug. 04. 23 |
5840 |
A Case of Evolut Valve Migration for TAV in SAV |
Kentaro Hayashida |
Aug. 04. 23 |
5839 |
Repeated Recurrent Restenosis in a Patient with Delayed Coronary Obstruction after TAVR |
Wei-Hsian Yin |
Aug. 04. 23 |
5838 |
Case of Transcatheter Heart Valve Embolrization in the Patient with Kyphosis |
Ju Han Kim |
Aug. 04. 23 |